Mochi Health, one of those implicated, is one of the largest telehealth providers of compounded GLP-1RAs. Eli Lilly maintains ...

Caribou is scaling back its operations, halting multiple programmes, and cutting staff to focus on two cancer programmes.

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

Swiss company Dr Mueller, a leading provider of filtration equipment for pharmaceutical manufacturers worldwide, will be among the exhibitors ...

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

Roche is set to invest $50bn in pharmaceuticals and diagnostics in the US over the coming five years to bolster its presence ...

The expiration of the FDA’s paediatric priority review voucher programme is creating uncertainty for rare disease drug ...

Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp, a healthcare ...

Following in the footsteps of several pharma companies, life sciences giant Thermo Fisher is doubling down on investments at ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

Pharmaceutical companies in Europe are requesting the EU to adopt drug pricing strategies comparable to the US.

Biogen Netherlands has received marketing authorisation from the UK MHRA for its Skyclarys to treat Friedreich's ataxia.